<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-650
Date of Submission: 2025-06-06

This report was submitted by a Pharmacist from Mcguire-Wade Medical Center concerning patient ANON-PX-8317. The subject is an adult female with a significant medical history including osteoarthritis, hypertension, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Subcutaneous route at a dosage of 295mg, initiated on 2025-04-24 for Hypercholesterolemia with the course ongoing.

On approximately 2025-05-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Nausea. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-650
report_date: '2025-06-06'
patient_details:
  patient_id: ANON-PX-8317
  gender: Female
  relevant_history:
  - osteoarthritis
  - hypertension
  - migraines
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 295mg
  route_of_administration: Subcutaneous
  start_date: '2025-04-24'
  indication_for_use: Hypercholesterolemia
adverse_reactions:
- symptom_name: Vomiting
  onset_date: '2025-05-24'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
- symptom_name: Nausea
  onset_date: '2025-05-24'
  severity: Mild
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Positive dechallenge
  naranjo_score: 10
reporting_facility: Mcguire-Wade Medical Center
reporter_type: Pharmacist
